
CITATION REPORT List of articles citing



DOI: 10.1016/j.euroneuro.2009.12.002 European Neuropsychopharmacology, 2010, 20, 139-45.

Source: https://exaly.com/paper-pdf/49630513/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
11	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, i-xii	2.6	
10	Mortality in schizophrenia: a measurable clinical endpoint. <i>Journal of Psychopharmacology</i> , 2010 , 24, 17-25	4.6	135
9	Head to head comparisons as an alternative to placebo-controlled trials. <i>European Neuropsychopharmacology</i> , 2012 , 22, 800-3	1.2	29
8	The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma. <i>European Neuropsychopharmacology</i> , 2012 , 22, 804-11	1.2	7
7	Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. <i>Schizophrenia Research</i> , 2012 , 138, 29-34	3.6	60
6	The quality of reporting of phase II and III trials for new antipsychotics: a systematic review. <i>Psychological Medicine</i> , 2015 , 45, 467-79	6.9	9
5	Detecting and Managing Adverse Effects of Antipsychotic Medications: Current State of Play. <i>Psychiatric Clinics of North America</i> , 2016 , 39, 275-311	3.1	20
4	Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective. <i>Therapeutic Advances in Psychopharmacology</i> , 2018 , 8, 319-326	4.9	9
3	Placebo-To be or not to be? Are there really alternatives to placebo-controlled trials?. <i>European Neuropsychopharmacology</i> , 2020 , 32, 1-11	1.2	5
2	Praktische Psychopharmakotherapie - Pages 427-430. 2012 , 427-430		

The Role of Noninferiority Designs in Bipolar Disorder Clinical Trials. **2015**, 49-57